Agenus Announces $340 Million Financing Package
Biotechnology company Agenus (NASDAQ:AGEN) announced an $85 million private placement with potential for up to $255 million in additional funding through warrants, totaling a possible $340 million. The financing is led by Commodore Capital and other institutional investors, aiming to support the Phase 3 ROBBIN clinical trial while extending cash runway until late 2031.